New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2012
16:25 EDTWMT, K, RDEA, AZN, BKS, ACHN, OTT, TWCOn The Fly: Closing Wrap
Stocks on Wall Street were lower following a pair of political developments in Europe. France’s incumbent president, Nicolas Sarkozy, came in second in the first round of the nation's elections and the Dutch cabinet failed to gain approval for a budget which included austerity measures, leading to their resignations. The European news, along with some disappointing data there and from China, weighed on the futures, which in turn led to a sharply lower open for the broader market. The market continued to move lower in the first hour of trading but then found a level where it began to build. The averages moved in a generally upward trend for the remainder of the session, as investors waited for the next round of earnings reports and for news later this week from the FOMC... ECONOMIC EVENTS: Domestically, little economic data of note was reported. Internationally, Markit's European composite purchase managers' index fell to 47.4 points while a flash Chinese PMI reading rose to 49.1 in April, with both of those figures signaling contraction... COMPANY NEWS: The New York Times said Wal-Mart (WMT) attempted to cover up bribery that it discovered at Wal-Mart de Mexico (WMMVY) and the retailers' shares were the Dow's worst performer, falling $2.91, or 4.66%, to $59.54... Kellogg (K) cut its full-year guidance as it said Europe's challenges were "more significant" than it expected and it sees Q1 challenges in some categories in the U.S. Shares sank $3.29, or 6.09%, to $50.70... MAJOR MOVERS: Among the notable gainers were Ardea Biosciences (RDEA), up $10.78, or 51.73%, to $31.62, after AstraZeneca (AZN) agreed to acquire the company for $32 per share, and Barnes & Noble (BKS), up $2.07, or 18.25%, to $13.41, as CNBC reported that Jana Partners is increasing its stake in the company to about 12%. Noteworthy losers included Achillion (ACHN), down $1.53, or 18.54%, to $6.74, following the company's report of Phase II study data for its lead hepatitis C treatment, and Otelco (OTT), down $5.37, or 44.64%, to $6.66, after it said Time Warner Cable (TWC) will not renew its existing contract for wholesale network connections, which made up almost 12% of Otelco’s consolidated revenue last year... INDICES: The Dow fell 102.09, or 0.78%, to 12,927.17; the Nasdaq dropped 30.00, or 1.00%, to 2,970.45; and the S&P 500 shed 11.59, or 0.84%, to 1,366.94.
News For WMT;K;RDEA;AZN;BKS;ACHN;OTT;TWC From The Last 14 Days
Check below for free stories on WMT;K;RDEA;AZN;BKS;ACHN;OTT;TWC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 10, 2014
10:00 EDTTWCOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:04 EDTTWCTime Warner Cable initiated with a Buy at Canaccord
Subscribe for More Information
05:58 EDTACHNStocks with implied volatility above IV index mean; DISH ACHN
Subscribe for More Information
September 9, 2014
12:02 EDTBKSOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CIEN FNSR PAY BKS PVH NAV BYI FTR JOY
10:29 EDTBKSBarnes & Noble says third parties see value in NOOK assets
Subscribe for More Information
10:18 EDTBKSBarnes & Noble says won't launch new bn.com in time for holiday season
Says "extremely happy" with Retail's Q1 performance, sees moderation of physical booksales decline. Says sees sales lift due to dispute between Amazon (AMZN) and Hachette. Regarding the launch of bn.com says making progress on development, but completion taking longer than expected. The company plans to launch the new site later this FY, but not in time for holiday season. Comments made on the Q1 earnings conference call.
08:37 EDTBKSBarnes & Noble's NOOK launched first co-branded tablet with Samsung
Subscribe for More Information
08:33 EDTBKSBarnes & Noble sees FY15 college SSS to decline low-single digits
For FY15 the company continues to expect both Retail comparable bookstore sales and Retail Core comparable bookstore sales to decline in the low-single digits. College comparable store sales are also expected to decline in the low-single digits. The company expects full fiscal year EBITDA losses in the NOOK segment to decline versus the prior year.
08:32 EDTBKSBarnes & Noble says making progress on separation of Retail and NOOK Media
Subscribe for More Information
08:32 EDTBKSBarnes & Noble reports Q1 EPS (56c), consensus (63c)
Reports Q1 revenue $1.2B, consensus $1.26B. “Core” comparable bookstore sales, which exclude sales of NOOK products, decreased 0.4% for the quarter. Comparable College store sales decreased 2.0% for the quarter, primarily impacted by the timing of the start of the back-to-school rush season as compared to last year. Comparable College store sales reflect the retail selling price of new or used textbooks when rented, rather than solely the rental fees received and amortized over the rental period. The NOOK segment had revenues of $70 million for the quarter, decreasing 54.3% from a year ago.
07:44 EDTTWCComcast price target raised to $72 from $60 at UBS
Subscribe for More Information
07:17 EDTTWCThe Wireless Association to hold a conference
Subscribe for More Information
06:29 EDTBKSBarnes & Noble results likely to highlight retail business strength, WSJ says
Subscribe for More Information
06:03 EDTACHNStocks with implied volatility above IV index mean; DISH ACHN
Subscribe for More Information
September 8, 2014
15:27 EDTBKSNotable companies reporting before tomorrow's open
Subscribe for More Information
14:13 EDTAZNConnecticut AG tells FDA to speed up generic Nexium
A news release from the Connecticut Attorney General George Jepsen, dated September 4, says: In comments to a Citizen Petition filed with the FDA, Attorney General George Jepsen called on the federal agency to expeditiously end several years of delays preventing the sale of a generic form of the drug esomeprazole magnesium , esomeprazole, currently marketed under the brand name Nexium. Nexium is the second highest-selling pharmaceutical drug in the United States, and delays in approving generic versions have cost consumers and government healthcare payers billions of dollars. In his comments, Attorney General Jepsen alleges that an agreement between drug manufacturers Ranbaxy (RBXLY) and AstraZeneca Pharmaceuticals (AZN), Nexium’s brand-name manufacturer, has prevented other drug-makers from launching a generic version of the drug, ultimately harming all consumers by artificially inflating prices. Ranbaxy was first-to-file with the FDA for approval of a generic form of Nexium. AstraZeneca sued Ranbaxy for patent infringement, and the dispute was settled by an agreement that provided financial incentives for Ranbaxy to delay entry of its generic into the consumer market. Reference Link
13:53 EDTBKSBarnes & Noble September volatility increases into Q1 and guidance
Subscribe for More Information
07:02 EDTAZNAstraZeneca announces availability of Bydureon pen 2mg
Subscribe for More Information
06:59 EDTTWCTWC workers to split $416M if Comcast deal falls through, Reuters says
In order to keep employees from leaving while federal regulators mull the final agreement, Time Warner Cable (TWC) workers will split $416M if the company's merger deal with Comcast (CMCSA) does not transpire, according to Reuters, citing a proxy statement. Reference Link
06:20 EDTTWCDiscovery: Comcast-TWC merger gives unfair advantage, NY Post reports
Discovery (DISCA) said Comcast's (CMCSA) takeover of Time Warner Cable (TWC) could give the combined company an unfair advantage over programmers, reports the New York Post. Discovery said the the company would have an advantage in carriage negotiations and in the advertising realms by refusing to share set-top-box data with programmers. Reference Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use